Market capitalization | $402.43m |
Enterprise Value | $362.53m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.85 |
P/S ratio (TTM) P/S ratio | 2.05 |
P/B ratio (TTM) P/B ratio | 3.18 |
Sales growth (TTM) Sales growth | 26.48% |
Turnover (TTM) Turnover | $196.03m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
7 Analysts have issued a Treace Medical Concepts Inc forecast:
7 Analysts have issued a Treace Medical Concepts Inc forecast:
Dec '23 | |
Current assets | 198 198 |
Fixed assets | 54 54 |
Total assets | 252 252 |
Dec '23 | |
Equity | 138 138 |
Debt capital | 114 114 |
Total capital | 252 252 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
Head office | United States |
CEO | John Treace |
Employees | 516 |
Founded | 2013 |
Website | www.treace.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.